Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• No. 5,484,776 describes a preparation process for controlled-release formulations of beta-blockers which are suitable for oral administration, the beta-blocker being reacted with a polysaccharide, preferably xanthan, in water, usually at elevated temperatures.
• WO 99/16417 describes aerosol sprays and soft gelatin capsules for buccal administration. As described, the described formulations are suitable for a broad spectrum of active ingredients.
• Beta-blockers are usually given for chronic indications, so that treatment can take months or years to complete. Further, the body weight of the treated animals (e.g., dogs or cats) will vary, so that variable dosability is also desirable. There is therefore a need for formulations for beta-blockers which combine high animal acceptance, good meterability and good long-term stability.
• a liquid water-based drug formulation for oral administration comprising at most 1% by weight of a beta-blocker in dissolved form, the formulation having rapid bioavailability.
• beta-blockers The drug group of beta-blockers is well known to those skilled in the art.
• beta-blockers include: carvedilol, atenolol, acebutolol, propranolol, pindolol, metoprolol, betaxolol, esmolol, nebivolol and bisoprolol.
• beta-blockers There are several subgroups of beta-blockers, such as B. beta-1 selective, beta-2 selective and unselective.
• Beta-1-selective beta-blockers are particularly suitable for the purposes of this invention, for example: atenolol, acebutolol, betaxolol, esmolol, metoprolol, nebivolol and in particular bisoprolol,
• the beta-blockers are used in the formulation according to the invention only in low concentrations, and usually in concentrations of at most 1 wt .-%, preferably at most 0.5 wt .-%. Typical concentration ranges for the beta-blockers are therefore from 0.001 to 1% by weight, preferably from 0.005 to 0.5% by weight, particularly preferably from 0.01 to 0.5% by weight.
• the solutions have a viscosity of 2 to 20 cP, preferably 4 to 15 cP, particularly preferably 5 to 10 cP.
• the pharmaceutical formulations of the invention may contain flavorings and / or flavorings.
• examples are sugars (usual concentration: 2 to 10 wt .-%, preferably 3 to 8 wt .-%) and vanilla flavor (usual concentration: 0.05 to 0.3 wt .-%, preferably 0.1 to 0, 2% by weight).
• sweeteners such as aspartame, cyclamate, saccharin, acesulfame, sucralose, thaumatin, neohesperidin, etc. used become.
• the recommended concentrations of the different sweeteners vary; but they belong to the generally available expertise.
• saccharin, especially the sodium salt is preferred. It is usually used in a concentration of 0.01-0.5 wt .-%, preferably 0.02-0.3 wt .-%.
• preservatives are chosen to work against bacteria and fungi.
• preservatives are organic acids, such as p-hydroxybenzoic acid esters, sorbic acid, benzoic acid, propionic acid, or their salts; Alcohols such. As benzyl alcohol, butanol or ethanol and quaternary ammonium compounds such as benzalkonium chloride.
• An example of a particularly suitable preservative is sodium benzoate.
• the preservative is usually in the inventive preparations in an amount of 0.01 to 1 wt .-%, preferably 0.02 to 0.6 wt .-%, particularly preferably from 0.02 to 0.4 wt .-% based included on the total weight of the preparation.
• aqueous solution by the addition of suitable buffer substances to a defined pH, usually in the range 2 to 10, preferably 3 to 9.
• weakly acidic pH values in the range from 3 to 7, in particular 3 to 5, are preferred.
• the pharmaceutical formulations according to the invention may contain further customary pharmaceutical auxiliaries and additives. It is also conceivable to add to the formulations, in addition to the beta-blocker, further active ingredients which improve the effect or extend the spectrum of action to other indications.
• the medicaments according to the invention have a rapid bioavailability. Accordingly, they are characterized in vitro by rapid release kinetics, i. at least 75% active substance is released within 30 minutes (measurement method see “Dissolution”, “Apparatus 2" in US Pharmacopeia 29 [2006]).
• the active ingredient reaches a high proportion in the blood plasma and the desired site of action and not z.
• the formulations according to the invention have good bio-digestibility, which is generally comparable to the bioavailability on intravenous administration.
• dose linearity Especially at low dosages should also be a linear (so-called “dose linearity") and accurate correlation between administered drug amount and resulting plasma concentration can be achieved to allow targeted dosing.
• formulations according to the invention are generally administered regularly over longer periods of time (eg daily), they should enable a repeated, precisely dosed application over a relatively long period of time.
• the pharmaceutical formulations according to the invention can be prepared by mixing the individual components in the required amounts. It can be z. For example, it is possible to introduce a part of the solvent, to mix in the other components, if necessary to adjust the pH and then to fill up to the required final volume with further solvent. Preferably, temperatures are in the production of about + 4O 0 C, preferably above +30 0 C avoided.
• the pharmaceutical preparations according to the invention are generally suitable for use in humans and animals. They are preferably used in animal husbandry and animal breeding in livestock, breeding, zoo, laboratory, experimental and hobby animals.
• the pharmaceutical formulations according to the invention are usually used for the treatment of cardiovascular diseases in animals, in particular in the treatment of heart failure.
• the livestock and breeding animals include mammals such as e.g. Cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur animals such as e.g. Mink, chinchilla, raccoon and birds such as e.g. Chickens, geese, turkeys, ducks, pigeons and bird species for home and zoo keeping.
• mammals such as e.g. Cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur animals such as e.g. Mink, chinchilla, raccoon and birds such as e.g. Chickens, geese, turkeys, ducks, pigeons and bird species for home and zoo keeping.
• Laboratory and experimental animals include mice, rats, guinea pigs, golden hamsters, dogs and cats.
• the hobby animals include rabbits, hamsters, guinea pigs, mice, horses, reptiles, corresponding birds, dogs and cats.
• the preparations according to the invention are preferably used in hobby animals such as horses, cats and dogs. They are particularly suitable for use in cats and especially dogs.
• Examples of preferred farm animals are beef, sheep, pork and chicken.
• formulations described herein are preferably for oral use.
• the formulations can be prepared by dissolving all components except the bisoprolol compound in an amount of phosphate buffer that is slightly less than the target final volume. Then the bisoprolol compound is dissolved in the batch, the pH adjusted and filled with phosphate buffer to the final volume.
• vanilla flavor 0.15% by weight of vanilla flavor
• vanilla flavor 0.20% by weight
• vanilla flavor 0.15% by weight of vanilla flavor
• vanilla flavor 0.15% by weight of vanilla flavor
• vanilla flavor 0.15% by weight of vanilla flavor
• vanilla flavor 0.25 wt% vanilla flavor
• vanilla flavor 0.15% by weight of vanilla flavor
• vanilla flavor 0.15% by weight of vanilla flavor
• vanilla flavor 0.15% by weight of vanilla flavor

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Emergency Medicine (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38180418

Family Applications (1)

Country Status (23)

Families Citing this family (5)

Family Cites Families (9)

• 2006
  • 2006-05-02 DE DE102006020604A patent/DE102006020604A1/de not_active Withdrawn
• 2007
  • 2007-04-19 KR KR1020087029343A patent/KR20090014183A/ko not_active Application Discontinuation
  • 2007-04-19 JP JP2009508161A patent/JP2009535368A/ja not_active Withdrawn
  • 2007-04-19 CA CA002650786A patent/CA2650786A1/en not_active Abandoned
  • 2007-04-19 EP EP07724362A patent/EP2015728A2/de not_active Withdrawn
  • 2007-04-19 WO PCT/EP2007/003425 patent/WO2007124869A2/de active Application Filing
  • 2007-04-19 US US12/299,127 patent/US20090264535A1/en not_active Abandoned
  • 2007-04-19 CN CNA2007800157542A patent/CN101431981A/zh active Pending
  • 2007-04-19 MX MX2008013873A patent/MX2008013873A/es unknown
  • 2007-04-19 RU RU2008147216/15A patent/RU2008147216A/ru not_active Application Discontinuation
  • 2007-04-19 BR BRPI0711140-1A patent/BRPI0711140A2/pt not_active IP Right Cessation
  • 2007-04-19 AU AU2007245911A patent/AU2007245911A1/en not_active Abandoned
  • 2007-04-27 PE PE2007000532A patent/PE20080149A1/es not_active Application Discontinuation
  • 2007-04-30 AR ARP070101872A patent/AR060730A1/es not_active Application Discontinuation
  • 2007-04-30 UY UY30315A patent/UY30315A1/es not_active Application Discontinuation
  • 2007-04-30 TW TW096115217A patent/TW200808373A/zh unknown
• 2008
  • 2008-10-29 CR CR10407A patent/CR10407A/es not_active Application Discontinuation
  • 2008-10-29 ZA ZA200809269A patent/ZA200809269B/xx unknown
  • 2008-10-29 CO CO08115883A patent/CO6180495A2/es not_active Application Discontinuation
  • 2008-10-29 EC EC2008008850A patent/ECSP088850A/es unknown
  • 2008-10-29 SV SV2008003080A patent/SV2008003080A/es not_active Application Discontinuation
  • 2008-10-29 GT GT200800235A patent/GT200800235A/es unknown
  • 2008-10-30 IL IL195034A patent/IL195034A0/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events